- Page 1:
The National Cohort A prospective e
- Page 4 and 5:
Applicants Applicants Applicants Cl
- Page 6 and 7:
Applicants IV
- Page 8 and 9:
Executive Summary 2. The National C
- Page 10 and 11:
Executive Summary 3. Scientific aim
- Page 12 and 13:
Executive Summary essary to address
- Page 14 and 15:
Executive Summary 7. Examples for s
- Page 16 and 17:
Contents A.2.4 major areas of expos
- Page 18 and 19:
Contents A.3.8.2 Social security da
- Page 20 and 21:
Contents A.6.4.2 Minimally detectab
- Page 22 and 23:
Abbreviations C.2 mEThOdS fOr STATI
- Page 24 and 25:
Abbreviations DXA Dual-energy x-ray
- Page 26 and 27:
Abbreviations CHS Cardiovascular He
- Page 28 and 29:
A.1 A.1 Introduction and overview a
- Page 30 and 31:
A.1 A.1 Introduction and overview s
- Page 32 and 33:
A.1 A.1 Introduction and overview T
- Page 34 and 35:
A.1 A.1 Introduction and overview m
- Page 36 and 37:
A.1 A.1 Introduction and overview
- Page 38 and 39:
A.1 A.1 Introduction and overview s
- Page 40 and 41:
A.1 A.1 Introduction and overview
- Page 42 and 43:
A.1 A.1 Introduction and overview P
- Page 44 and 45:
A.1 A.1 Introduction and overview t
- Page 46 and 47:
A.1 A.1 Introduction and overview A
- Page 48 and 49:
A.2 A.2. Scientific background and
- Page 50 and 51:
A.2 A.2. Scientific background and
- Page 52 and 53:
A.2 A.2. Scientific background and
- Page 54 and 55:
A.2 A.2. Scientific background and
- Page 56 and 57:
A.2 A.2. Scientific background and
- Page 58 and 59:
A.2 A.2. Scientific background and
- Page 60 and 61:
A.2 A.2. Scientific background and
- Page 62 and 63:
A.2 A.2. Scientific background and
- Page 64 and 65:
A.2 A.2. Scientific background and
- Page 66 and 67:
A.2 A.2. Scientific background and
- Page 68 and 69:
A.2 A.2. Scientific background and
- Page 70 and 71:
A.2 A.2. Scientific background and
- Page 72 and 73:
A.2 A.2. Scientific background and
- Page 74 and 75:
A.2 A.2. Scientific background and
- Page 76 and 77:
A.2 A.2. Scientific background and
- Page 78 and 79:
A.2 A.2. Scientific background and
- Page 80 and 81:
A.2 A.2. Scientific background and
- Page 82 and 83:
A.3 A.3 Study design ment instrumen
- Page 84 and 85:
A.3 A.3 Study design Table 3.2: Des
- Page 86 and 87:
A.3 A.3 Study design Table 3.3: Dis
- Page 88 and 89:
A.3 A.3 Study design the participan
- Page 90 and 91:
A.3 A.3 Study design with a prepare
- Page 92 and 93:
A.3 A.3 Study design rural areas, t
- Page 94 and 95:
A.3 A.3 Study design A.3.2 Baseline
- Page 96 and 97:
A.3 A.3 Study design Modules 70 Int
- Page 98 and 99:
A.3 A.3 Study design ovarian carcin
- Page 100 and 101:
A.3 A.3 Study design Table 3.5: Spe
- Page 102 and 103:
A.3 A.3 Study design depression and
- Page 104 and 105:
A.3 A.3 Study design to the extent
- Page 106 and 107:
A.3 A.3 Study design ers to vaccina
- Page 108 and 109:
A.3 A.3 Study design certain foods)
- Page 110 and 111:
A.3 A.3 Study design A short instru
- Page 112 and 113:
A.3 A.3 Study design ticipants and
- Page 114 and 115:
A.3 A.3 Study design a resting time
- Page 116 and 117:
A.3 A.3 Study design index, convent
- Page 118 and 119:
A.3 A.3 Study design Although the i
- Page 120 and 121:
A.3 A.3 Study design air and then t
- Page 122 and 123:
A.3 A.3 Study design hemorrhages (0
- Page 124 and 125:
A.3 A.3 Study design genetics of BM
- Page 126 and 127:
A.3 A.3 Study design hand grip stre
- Page 128 and 129:
A.3 A.3 Study design Project title
- Page 130 and 131:
A.3 A.3 Study design diseases in va
- Page 132 and 133:
A.3 A.3 Study design associations,
- Page 134 and 135:
A.3 A.3 Study design Informed Conse
- Page 136 and 137:
A.3 A.3 Study design 6. Since being
- Page 138 and 139:
A.3 A.3 Study design the possible d
- Page 140 and 141:
A.3 A.3 Study design A.3.5 Collecti
- Page 142 and 143:
A.3 A.3 Study design Blood In addit
- Page 144 and 145:
A.3 A.3 Study design the anterior n
- Page 146 and 147:
A.3 A.3 Study design study. For exa
- Page 148 and 149:
A.3 A.3 Study design large-size sto
- Page 150 and 151:
A.3 A.3 Study design routinely prep
- Page 152 and 153:
A.3 A.3 Study design Subjects who m
- Page 154 and 155:
A.3 A.3 Study design A.3.6.3 reliab
- Page 156 and 157:
A.3 A.3 Study design In addition, a
- Page 158 and 159:
A.3 A.3 Study design Disease Questi
- Page 160 and 161:
A.3 A.3 Study design Data routinely
- Page 162 and 163:
A.3 A.3 Study design tial misclassi
- Page 164 and 165:
A.3 A.3 Study design � The KORA c
- Page 166 and 167:
A.3 A.3 Study design Table 3.16: Co
- Page 168 and 169:
A.3 A.3 Study design Table 3.17: Co
- Page 170 and 171:
A.4 A.4 Integrated Data Management
- Page 172 and 173:
A.4 A.4 Integrated Data Management
- Page 174 and 175:
A.4 A.4 Integrated Data Management
- Page 176 and 177:
A.4 A.4 Integrated Data Management
- Page 178 and 179:
A.4 A.4 Integrated Data Management
- Page 180 and 181:
A.4 A.4 Integrated Data Management
- Page 182 and 183:
A.5 A.5 Methods for quality assuran
- Page 184 and 185:
A.5 A.5 Methods for quality assuran
- Page 186 and 187:
A.5 A.5 Methods for quality assuran
- Page 188 and 189:
A.5 A.5 Methods for quality assuran
- Page 190 and 191:
A.5 A.5 Methods for quality assuran
- Page 192 and 193:
A.5 A.5 Methods for quality assuran
- Page 194 and 195:
A.5 A.5 Methods for quality assuran
- Page 196 and 197:
A.6 A.6 Planned statistical analyse
- Page 198 and 199:
A.6 A.6 Planned statistical analyse
- Page 200 and 201:
A.6 A.6 Planned statistical analyse
- Page 202 and 203:
A.6 A.6 Planned statistical analyse
- Page 204 and 205:
A.6 A.6 Table Planned 6.4: Expected
- Page 206 and 207:
A.6 A.6 Planned statistical analyse
- Page 208 and 209:
A.6 Planned statistical analyses an
- Page 210 and 211:
A.6 A.6 Planned statistical analyse
- Page 212 and 213:
A.6 A.6 Planned statistical analyse
- Page 214 and 215:
A.6 A.6 Planned statistical analyse
- Page 216 and 217:
A.6 A.6 Planned statistical analyse
- Page 218 and 219:
A.7 A.7 Ethical aspects logical/gen
- Page 220 and 221:
A.7 A.7 Ethical aspects The more ex
- Page 222 and 223:
A.7 A.7 Ethical aspects pants, trav
- Page 224 and 225:
A.7 A.7 Ethical aspects Data handli
- Page 226 and 227: A.7 Table 7.2 Availability of ident
- Page 228 and 229: A.7 A.7 Ethical aspects Should bios
- Page 230 and 231: A.7 A.7 Ethical aspects ing finding
- Page 232 and 233: A.7 A.7 Ethical aspects 206
- Page 234 and 235: C.1 C.1 Annex: Description of the s
- Page 236 and 237: C.1 C.1 Annex: Description of the s
- Page 238 and 239: C.1 C.1 Annex: Description of the s
- Page 240 and 241: C.1 C.1 Annex: Description of the s
- Page 242 and 243: C.1 C.1 Annex: Description of the s
- Page 244 and 245: C.1 C.1 Annex: Description of the s
- Page 246 and 247: C.1 C.1 Annex: Description of the s
- Page 248 and 249: C.1 C.1 Annex: Description of the s
- Page 250 and 251: C.1 C.1 Annex: Description of the s
- Page 252 and 253: C.1 C.1 Annex: Description of the s
- Page 254 and 255: C.1 C.1 Annex: Description of the s
- Page 256 and 257: C.1 C.1 Annex: Description of the s
- Page 258 and 259: C.1 C.1 Table Annex: 1: Cluster Des
- Page 260 and 261: C.1 C.1 Annex: Description of the s
- Page 262 and 263: C.1 C.1 Annex: Description of the s
- Page 264 and 265: C.1 C.1 Annex: Description of the s
- Page 266 and 267: C.1 C.1 Annex: Description of the s
- Page 268 and 269: C.1 C.1 Annex: Description of the s
- Page 270 and 271: C.1 C.1 Annex: Description of the s
- Page 272 and 273: C.1 C.1 Annex: Description of the s
- Page 274 and 275: C.1 C.1 Annex: Description of the s
- Page 278 and 279: C.1 C.1 Annex: Description of the s
- Page 280 and 281: C.1 C.1 Annex: Description of the s
- Page 282 and 283: C.2 C.2 Annex: Methods for Statisti
- Page 284 and 285: C.2 C.2 Annex: Methods for Statisti
- Page 286 and 287: C.2 Table S6.5: Sample size needed
- Page 288 and 289: C.2 C.2 Annex: Methods for Statisti
- Page 290 and 291: C.2 C.2 Annex: Methods for Statisti
- Page 292 and 293: C.2 C.2 Annex: Methods for Statisti
- Page 294 and 295: C.2 C.2 Annex: Methods for Statisti
- Page 296 and 297: C.3 References 17. Keil, U., et al.
- Page 298 and 299: C.3 References 50. Benjamin, E.J.,
- Page 300 and 301: C.3 References 85. Calle, E.E. and
- Page 302 and 303: C.3 References 121. Walter, R., D.J
- Page 304 and 305: C.3 References 155. Ross, R., Ather
- Page 306 and 307: C.3 References 189. Ghiotto, F., et
- Page 308 and 309: C.3 References 225. Schmidt, C.O.,
- Page 310 and 311: C.3 References 260. Eussen, S., et
- Page 312 and 313: C.3 References 294. McCrae, R.R. an
- Page 314 and 315: C.3 References 327. Lynch, J.W., G.
- Page 316 and 317: C.3 References 360. Mair, C., A.V.
- Page 318 and 319: C.3 References 395. Lesourd, B., Nu
- Page 320 and 321: C.3 References 431. Statistisches B
- Page 322 and 323: C.3 References 462. Bundeszentrale
- Page 324 and 325: C.3 References 494. Rammstedt, B. a
- Page 326 and 327:
C.3 References 526. Mack, F., et al
- Page 328 and 329:
C.3 References 560. Palatini, P., A
- Page 330 and 331:
C.3 References 590. Greenland, P.,
- Page 332 and 333:
C.3 References 623. Olin, A.C., et
- Page 334 and 335:
C.3 References 658. Pate, R.R., J.R
- Page 336 and 337:
C.3 References 691. Zenge, M.O., et
- Page 338 and 339:
C.3 References 727. Ryu, O.H., et a
- Page 340 and 341:
C.3 References 757. BSI-Standard 10
- Page 342 and 343:
C.3 References 790. Davis, C.E., et
- Page 344:
C.3 References 822. Hegenscheid, K.